Supreme Court punts, mostly

Although the pharmaceutical industry failed to win its case against Maine's drug price control law in the U.S. Supreme Court, states also were denied a precedent to back their efforts to use Medicaid to leverage better prices from pharmaceutical companies. Indeed, the price control advocates may have to wait for a decision from the Bush administration.

Acting on narrow legal issues, The Supreme Court last week rejected the contention that the Maine Rx law violates the U.S. Constitution and ruled that industry had not established that implementation of Maine Rx would violate federal Medicaid law. The high court struck down an injunction

Read the full 1016 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE